ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2008

Initial Evaluation of a Localized Scleroderma (LS) Clinical Activity Measure

Suzanne C. Li1, Kathryn S. Torok2, Christina Kelsey3, Mara L Becker4, Fatma Dedeoglu5, Robert C. Fuhlbrigge6, Gloria C. Higgins7, Sandy D. Hong8, Maria F. Ibarra9, Ronald Laxer10, Thomas G. Mason II11, Marilynn G. Punaro12, Elena Pope13, C. Egla Rabinovich14 and Katie G. Stewart12, 1Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, 2Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, 5Division of Immunology, Boston Children's Hospital, Boston, MA, 6Pediatric Rheumatology, Childrens Hospital, Boston, MA, 7Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, 8Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, 9Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, 10Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 11Rheumatology, Mayo Clinic Rochester, Rochester, MN, 12Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 13Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, 14Pediatric Rheumatology, Duke University Medical Center, Durham, NC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Activity score, pediatric rheumatology and scleroderma

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

LS commonly causes severe morbidity for the growing child. Optimal therapy is not known and the lack of an agreed-upon standard for assessing disease state and monitoring treatment response has hindered treatment comparison. To work towards conducting comparative effectiveness studies, an LS-focused Childhood Arthritis and Rheumatology Research Alliance subgroup developed a clinical disease activity measure (LS Activity Score, Arthritis Care Res 2012 DOI: 10.1002/acr.21687), based upon LoSSI and LOCUS studies (J Rheumatol 2008;35:640; Arthritis Rheum 2011;63 Suppl:S955).  The LS Activity Score scores for 7 parameters (erythema, violaceous color, waxy or white lesion, skin thickness of lesion edge, lesion warmth, new lesion, change in lesion size) in affected anatomic sites, with body divided into 19 sites.

Objective: To evaluate the validity and reliability of the LS Activity Score. 

Methods:  

A two-day workshop meeting was conducted in which 13 pediatric rheumatologists and a pediatric dermatologist reviewed LS clinical measures and conducted a reliability of scoring study.  The 14 raters evaluated 13 juvenile LS (jLS) patient volunteers with the LS Activity Score in a random order twice in one day. For each patient, raters were told which anatomic sites to assess (1-2/patient); new lesion and lesion size change were not scored because they require prior patient evaluation. Raters scored Physician Global Assessment (PGA, 0-100 mm) of disease activity (DA) and PGA of disease damage (DD) for each patient based upon evaluated anatomic sites. We hypothesized the LS Activity Score would have moderate to high correlation with PGA-DA (convergent validity) and low correlation with PGA-DD (divergent validity). Spearman’s rho was calculated to assess level of correlation, and intraclass correlation coefficients (ICC) calculated to assess intra- and inter-rater reliability (0.20-0.39 considered low, 0.40-0.59 moderate, >0.60 high).

Results:

Mean age of jLS patients was 13.2 years, most common subtype was linear scleroderma (4 limb, 4 head). Mean patient LS Activity Scores ranged from 0.50 to 9.28 (4-52% of maximum possible score), mean PGA-DA from 4.0 to 59.6. There was a high correlation between LS Activity score and PGA-DA (ρ= 0.94), and low with PGA-DD (ρ= -0.121).  Raters showed moderate inter-rater reliability for LS Activity Score and PGA-DA, with nearly all showing moderate to high intra-rater reliability for these scores (Table). Among the different parameters, violaceous color and lesion warmth had the lowest inter-rater reliability.

Table: Inter rater and intra-rater reliability of LS Activity score

Domains

 Round 1

ICC (95% CI)

Round 2

ICC (95% CI)

LS Activity Score:

 

 

Inter-rater reliability

0.564 (.38, .79)

0.628 (.43, .83)

Intra-rater reliability (median)

 

0.804 [range 0.464-0.910]

PGA-DA:

 

 

Inter-rater reliability

0.566 (.38, .79)

0.516 (.33, .76)

Intra-rater reliability (median)

 

0.734 [range 0.369-0.955]

LS Activity Score parameters: inter-rater reliability

 

 

Erythema

0.392 (.25, .59)

0.483 (.33, .67)

Violaceous color

0.187 (.09, .36)

0.140 (.06, .29)

Waxy or white lesion

0.429 (.29, .63)

0.518 (.37, .70)

Lesion warmth

0.197 (.10, .37)

0.148 (.07, .30)

Skin Thickness of lesion edge

0.407 (.26, .60)

0.307 (.18, .50)

Conclusion:    We demonstrate initial construct validity for LS Activity score, and found moderate inter-rater reliability. Additional studies are needed to fully evaluate this measure’s validity. More training for the violaceous color and lesion warmth parameters may improve the measure’s reliability.


Disclosure:

S. C. Li,
None;

K. S. Torok,
None;

C. Kelsey,
None;

M. L. Becker,
None;

F. Dedeoglu,
None;

R. C. Fuhlbrigge,
None;

G. C. Higgins,
None;

S. D. Hong,
None;

M. F. Ibarra,
None;

R. Laxer,

Novartis Pharmaceutical Corporation,

2;

T. G. Mason II,
None;

M. G. Punaro,
None;

E. Pope,
None;

C. E. Rabinovich,
None;

K. G. Stewart,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/initial-evaluation-of-a-localized-scleroderma-ls-clinical-activity-measure/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.